• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Articles by Marie Powers

'Pharma 3.0' is Changing the Rules for Players in Health Care

Feb. 16, 2011
By Marie Powers
Pharmaceutical companies are dramatically increasing their investments in new and innovative technologies to meet the demands of a patient-empowered, data-driven, outcomes-focused health care marketplace. In the last year alone, pharma investment in smart phone apps, educational websites, social media platforms, wireless devices and other programs increased by 78 percent, as traditional pharmas embrace a role that goes far beyond developing and manufacturing drugs.
Read More

Idenix Stock Tumbles on Mixed Clinical Program Updates

Feb. 11, 2011
By Marie Powers
Idenix Pharmaceuticals Inc. provided updates to three key clinical development programs on Wednesday. Unfortunately for investors, two were disappointments, though one of those might ultimately have a silver lining for the Cambridge, Mass.-based company.
Read More

Risk-Averse Funding, Lack of Tools Slow Research Progress

Feb. 10, 2011
By Marie Powers
More than 75 percent of research activity on human proteins continues to focus on the 10 percent of proteins that were known before the mapping of the human genome was completed in 2000, even though many more proteins have been genetically linked to disease during the ensuing decade. Risk-averse funding and peer review systems as well as a dearth of research tools – such as antibodies and chemical inhibitors needed to study proteins – share blame, a group of research scientists posited this week in Nature.
Read More

BioNet Holding Banks on Scil Proteins with $33M Financing

Feb. 9, 2011
By Marie Powers

Theravance Climbs as COPD Program Enters Phase III

Feb. 4, 2011
By Marie Powers
GlaxoSmithKline plc and Theravance Inc. achieved major milestones this week in a pair of clinical development programs focused on treatments for patients with chronic obstructive pulmonary disease (COPD).
Read More

BioNet Holding Banks on Scil Proteins with $33M Financing

Feb. 3, 2011
By Marie Powers
Privately held Scil Proteins GmbH, of Halle, Germany, has concluded a financing round with BioNet Holding GmbH, worth €24 million ($33.1 million). The funds will be used to move two preclinical products derived from Scil Proteins' Affilin scaffold technology platform into Phase I studies over the next three years.
Read More

Opko Health Pays $10M to Acquire Curna

Feb. 2, 2011
By Marie Powers
Opko Health Inc. plunked down $10 million cash this week to acquire Curna Inc., a privately held drug discovery company based in Jupiter, Fla., that has largely flown under the radar since it was launched in 2008 with technology from the Scripps Research Institute.
Read More

Eisai's Eritoran Setback Puts Sepsis Drug on Critical List

Jan. 26, 2011
By Marie Powers
The failure of Eisai Inc.'s eritoran (E5564) to meet its primary Phase III endpoint of reducing 28-day all-cause mortality in patients with severe sepsis may have relegated yet another candidate to the graveyard of failures for this indication.
Read More

MannKind Shares Sink on 2nd Afrezza Complete Response

Jan. 21, 2011
By Marie Powers
MannKind Corp. took one squarely on the chin Thursday as the market responded to breaking news late Wednesday that the FDA had issued a second complete response letter for inhaled insulin candidate Afrezza (insulin human [rDNA origin] to treat adults with Type I and Type II diabetes. (See BioWorld Today, Jan. 20, 2011.)
Read More

GSK, ChemoCentryx Move to Phase III with Crohn's Drug

Jan. 13, 2011
By Marie Powers
Fewer than five years after inking a partnership deal focused on treatments for inflammatory disorders, privately held ChemoCentryx Inc., of Mountain View, Calif., and GlaxoSmithKline plc, of London, started treating the first patient with Crohn's disease in their initial induction study comparing Traficet-EN (CCX282-B) – now designated GSK1605786 ('786) – to placebo. The Phase III program is being conducted through GSK's Center of Excellence for External Drug Discovery (CEEDD).
Read More
Previous 1 2 … 161 162 163 164 165 166 167 168 169 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 7, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • Illustration of cancer tumor on pancreas

    PIKfyve enzyme is target to ‘starve’ pancreatic cancer cells

    BioWorld
    A metabolic vulnerability of pancreatic ductal adenocarcinoma (PDAC) could be used to address this type of cancer that often resists treatments. Scientists at the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 6, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe